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This study determines whether risk allele frequencies (RAFs) for common 
diseases can be generalized in genome wide association surveys (GWASs) that are done 
in different populations other than the original study population. To test this, the study 
compares RAFs gathered from the NHRI-EBI GWAS Catalog and 1000 Genomes 
Project by study population and checks if there is bias towards the study population. If 
the trend is present, the study looks to answer the question of whether or not this is due to 
an inherent bias from the study population, or a pre-ascertained bias in the genotyping 
single nucleotide polymorphism (SNP) chip array. To test bias in the technology, the 
study compares allele frequencies for disease SNPs and non-disease SNPs on Illumina1M 
and Affymetrix 6.0 genotyping arrays. If the bias still persists, then there is an inherent 
bias due to the study population alone. At this point, the study will examine the role of 
other contributing factors to differences in disease allele frequencies across populations. 
These include: type of disease, number of participants in the GWAS, whether alleles have 
a large effect, etc. This study potentially contributes the overall field of population 
genetics and personalized medicine. Essentially, the goal is to ensure that the information 
attained can be used to create models that could correct potential bias in GWAS studies. 
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INTRODUCTION 
 Today’s perception on medicine is changing. The once common belief that every 
individual is equally susceptible to a certain type of disease has been challenged and 
disproven. As such, it is now known that an individual’s genetic makeup has a strong 
influence on the susceptibility to common diseases. Because this is the case, personalized 
medicine has seen an increase in importance. Unfortunately, it is impractical to try and 
genotype every individual in hopes of finding exact recommendations of treatment based 
on the genes that individual has. Thus, bioinformatics and population genetics comes into 
play. Observing the average genotypes of a population provides a more practical solution. 
By taking into account common risk variants of a population, a trained professional will 
be able to apply a statistically correct treatment for an individual who belongs to that 
particular population. The best way to obtain information about the genetic make-up of a 
population is conducting genome wide association surveys (GWASs). These surveys 
show trends in risk alleles and risk allele frequencies among different populations for 
certain diseases or traits. Thus, one can pinpoint correlations between other traits and the 
occurrence of a specific disease or ailment: as a result, we can potentially modify 
different treatments for different groups of people based on their genetic makeup of their 
population of origin—again, we see the connection between the field of population 
genetics and personalized medicine, and how it can benefit the health sector. 
 This line of thinking has been implemented before, however, questions persist 
about the validity of using a limited set of populations to treat an almost 
incomprehensibly diverse set of people. The biggest question stems from the fact that 
most genetic information comes from the “European” source population—thus, there 
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may be bias in allele frequencies skewed to over-representing European risk allele 
frequencies, and under-representing African, East Asian, South Asian, American, and 
Mixed population risk allele frequencies (RAFs). There have been studies to test whether 
RAFs can be generalized to and from different population. Carlson et al. found that single 
nucleotide polymorphism (SNPs) risk allele frequencies could indeed be replicated across 
populations for certain common diseases11. However, while directionality of these risk 
allele frequencies was the same, magnitude differed (if RAFs were high for a certain 
population in a GWAS done in European source population, then they would be generally 
high for that same population if the GWAS was done in another source population; 
however, the magnitude of the RAF would be different). Thus, caution was emphasized 
when trying to generalize RAF’s across population. Virlogeux et al. performed a similar 
experiment, except focused on prostate cancer SNPs alone. Using similar methods to test 
for generalization, they found similar results to Carlson and his team2.  
 With the field of population genetics growing, it is important to realize that the 
data used by previous research is now outdated. In addition, it under-represents the total 
amount of SNP data that is now present in databases such as the National Human 
Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS 
Catalog and 1000 Genomes Project. In addition, few previous studies have raised the 
question of whether or not bias could be due to SNP chip arrays used for GWASs being 
inherently skewed toward European risk allele frequencies (this is a problem of 
technology rather than human bias through location of undertaken GWAS’s). 
 While the current study will use similar methods and techniques to test potential 
biases and generalization of source populations for RAFs for common diseases in 
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GWAS’s as the previous studies, it differs in terms of the databases used. The current 
study uses the most updated databases, and significantly more SNP data (6000 SNPs) 
compared to others. Preliminary data suggests that there is indeed a bias towards a source 
population. However, more statistical evidence needs to be done to ensure that this is the 
case. Regardless, this study will seek to explain why this observation occurs. If the biased 
trends continue to be observed when comparing data for SNPs associated with more than 
just common diseases, then there is a problem with the SNP array technology. However, 
if this is not the case, then it is evident that there is a bias towards the fact that GWAS’s 
are done in a certain source population, and it is not an inherent bias in the technology 
used. At this point, the study will seek to identify the role of other contributing factors to 
differences in disease allele frequencies across populations. Some of these factors 
include: strength and size of effect of certain SNPs, the disease type, number of 
participants in the GWAS, whether the SNP is in an area of natural selection, and how 
related the different populations are. 
 Ultimately, the importance of this research stems from two points. The first, more 
direct reason, stems from ensuring that the information garnered from this study can be 
used to improve future models that seek to correct biases in GWAS studies. The second, 
more broad reason, is to ensure that any treatments based on the scope of personalized 








A growing trend in the health field today is personalized medicine. Researchers 
have, for a while now, realized that by understanding the genetic makeup of an 
individual, more accurate and precise treatments can be administered to patients who 
suffer from specific common diseases6. This relatively new way of thinking is not 
without its drawbacks, however. For example, it seems wholly impossible in terms of 
cost, time, and efficiency to accrue the genetic data of each and every individual. Instead, 
a more practical solution to this dilemma is to gather the genetic data of groups of related 
individuals by population of ancestry. These individuals, understandably, have a 
significantly higher chance of having similar genetic make-up than individuals who have 
differing ancestors. These types of studies are not uncommon today: they are collectively 
known as genome wide association studies (GWASs), and are usually done in 
conjunction with the field of bioinformatics and population genomics. These studies are 
conducted by associating different single nucleotide polymorphisms (SNPs) in 
individuals from a population, and associating them with a risk allele frequency (RAFs) 
for a certain common disease. From this data, one can potentially compare the RAFs of 
different populations for common diseases. Individuals from populations that have higher 
RAFs for a certain disease are said to have a greater chance of getting that disease7. Thus, 
proactive measures can be instituted for those individuals to prevent the onset of that 
disease before it occurs, or zeroed-in treatment on specific gene segments that have the 
highest chance of causing the individual to be susceptible for the disease can be 
administered. 
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 While this method has its merits, it does come with limitations in terms of the 
validity and accuracy of the data reported. One of the biggest questions that is asked is 
whether results from a GWAS done in one source population can be replicated and 
generalized in another population. One such study that sought to answer the question as 
to whether there was some bias in modern day GWASs was conducted by Carlson et al., 
only three years ago in 2013. Carlson and his team asked the question as to whether or 
not GWASs done in a European source population could be generalized to non-European 
populations1. His team’s methods involved looking at allele frequencies of certain SNPs 
across multiple types of diseases across populations. Ultimately, if the allele frequencies 
could indeed be generalized, then previous GWAS results could be deemed valid. 
However, if it was found that they do not generalize (allele frequencies for SNPs 
associated with a disease in a population differ depending on the source population of the 
GWAS), then changes must be made in terms of how GWASs are conducted, or, we must 
find a way to manipulate existing data to better fit the trends that are present. Carlson et 
al. found that the directionality of the results for populations remained the same, 
regardless of source population1. That is to say, if the risk allele frequency for a certain 
SNP in an African population (used as an example here) was higher than the risk allele 
frequency of a European population according to a GWAS done in a European source 
population, then we can expect to see the same trend in a similar GWAS done in a non-
European source population. However, what is important to note is that the magnitude of 
effect was different1. In essence, the reported RAF may not be as strong or weak, 
depending upon what source population the GWAS was conducted in. As a result, 
Carlson et al. strongly suggested that caution should be used when generalizing results 
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from a GWAS done with European source populations. While not wholly invalid, there is 
still some cause for concern1. 
 A similar study was done by Virlogeux et al. last year in 2015. Instead of 
focusing on many common diseases, his team focused on prostate cancer, and the SNPs 
that were associated with it2. Clinical data suggests that those with African ancestry are 
more susceptible to acquiring prostate cancer—this can be partially explained by the fact 
that those with this ancestry have a higher chance of having SNPs that are pre-markers 
for the disease (in terms of GWASs, the RAF for SNPs that are associated with prostate 
cancer are higher in African populations than other population, specifically European 
populations)2,8. While clinical data does support this genetic hypothesis, Virlogeux and 
his teams wanted to ensure that there was enough validity in the GWASs that led to this 
genetic data, so that it could properly be used in support of certain treatments. This study 
mainly arose from the fact that most of the GWASs were done in a European source 
population. All of these results could potentially be biased because they were all 
compared to the same source! Thus, Virlogeux et al., using similar methods as Carlson et 
al., sought ensure that GWASs could be generalized across populations, specifically for 
prostate cancer-related SNPs. His team found analogous results to Carlson et al., 
suggesting that while directionality of the results from GWASs done with different 
source populations are the same, magnitude differs2. Thus, caution, again, is suggested. 
 Both of these studies have weaknesses that the current experiment will seek to 
alleviate. The weaknesses stem from the fact that population genetics, and GWASs in 
general of this nature, is an ever-growing field. The results from even one year ago may 
not hold true today as more and more SNP data comes through and is reported. My study 
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will utilize more SNP data gathered from the National Human Genome Research Institute-
European Bioinformatics Institute (NHGRI-EBI) GWAS Catalog and 1000 Genomes 
Project (around 6000 SNPs from 6 populations) than both of the previous two studies 
mentioned. In addition, that SNP data will be the up-to date (corrections are made about 
SNP data all the time). This influx of data can expose what was not clearly evident before 
when an incomplete data set was used. In addition, it has already been proven that 
previous techniques in gathering SNP data was flawed and can be consistently incorrect 
in certain gene segments9. Essentially, the current experiment will update previous ones. 
 While having an updated data set to ensure validity of GWAS studies is 
important, an equally important question to answer is why trends are the way they are. If 
there is not a bias towards the source population, then there is no need to answer this 
question (the null hypothesis is that there is no bias). However, if there is a bias towards 
the source population of the GWAS, one must answer the question of why this is the 
case. There are two possible explanations for this. The first, is that there is an inherit bias 
from the source population, skewing the RAFs towards itself in other populations. The 
second, is that there is a problem with the technology used to gather the GWAS data—the 
SNP chip arrays are biased towards a certain population (most likely European because 
that is where most GWASs take place). Lachance et al. found that “genotyping arrays 
contain biased sets of pre-ascertained SNPs”—indicating that the biases that we see are 
due to technology, rather than the data gathered from the populations themselves3. Clark 
et al. found similar results when looking at HapMap genotyping4. There are plenty of 
specific factors that affect the SNP data, and lead to these certain biases. These include 
number of individual data gathered, how old the individual data is, how much admixture 
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occurred in the individuals’ data, only intermediate risk allele frequencies having power, 
etc.3,4. 
 The current research will first explore if there is or is not bias in source 
populations for GWASs. To do this, RAFs for SNPs in different populations will be 
compared with differing source populations. The null hypothesis is that there is no bias. 
Previous research has suggested that there is no significant bias in directionality towards 
the source population (though magnitude does differ between populations), however, 
outdated SNP databases and the influx of new, updated SNP data suggest that this result 
may no longer be true. If the alternative hypothesis, that there is such a bias, is proven 
true, then I will test why this is the case. To test if there is a pre-ascertained bias in the 
SNP chip array technology, as previous research has indicated is a real possibility, the 
allele frequencies for disease SNPs and non-disease SNPs on Illumina1M and Affymetrix 
6.0 genotyping arrays will be compared. If the bias no longer persists, then there is an 
inherit bias in the source population rather than the technology. This may be due to the 
fact that, as previous research indicates, GWASs lack statistical power unless the RAFs 





























Figure 1: Flow chart of  f irst steps of method. The flow chart above shows the general process in gathering SNP data from two databases, merging 
them, and what information was kept at each stage. 
 
To begin this study, SNP databases had to be collected in order actually observe 
any trends. As a reference, the flowchart above describes the general process of the 
databases that were collected, and what was done so that the final data set had necessary 
information. The NHGRI-EBI Catalog was chosen because it had the most easily 
accessible and largest collection of SNPs to use for free. The database did not include risk 
allele frequencies for the five populations of study (EUR, AFR, SAS, EAS, AMR), or the 
26 sub-populations of study (as found 1000 Genomes website). To incorporate this data, 
the 1000 Genomes database was merged with the NHGRI-EBI Catalog using code 
written in both Perl and R. From there, manual editing was done to delete SNPs that still 
had missing information that could not easily be retrieved. In addition, random SNP 
checking was done to verify that the merge successfully matched the SNP pairs from 
each database.  
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 From here, the risk allele frequency for each population for each SNP 
(approximately 5768 SNPs) was compared.  The risk allele frequencies for each 
population was also compared after the new database was split up into smaller databases 
based on what disease the SNP was associated with (ex. Cancer (general), breast cancer, 
prostate cancer, ulcerative colitis, rheumatoid arthritis, Alzheimer’s and dementia, etc.).  
Any trends or biases were noted. There was special emphasis in the general cancer 
category (most GWAS data involved SNPs that were associated with cancer). 
Afterwards (not shown on flowchart), the database was then split up between 
SNPs that were known to come from studies that were done in the Illumina chip, and 
those that were known to be done on the Affymetrix chip. The same process in 
comparing frequencies was done to see if there were any trends.   
 Lastly, the database (being restored to the point before it was split up by chip 
type) was split up based on whether the SNP was ancestral or derived. From there, the 
same general process was done to compare allele frequencies between each population 
and disease type. However, as opposed to just comparing the five main populations, the 
frequencies in the 26 sub-populations were also looked at (this data was found in the 
1000 Genomes Project database). The risk allele frequencies that were gathered were 
used to calculate a genetic risk score (GRS) for each population for certain diseases. The 






The formula is essentially the natural log of the product sum of the manipulation of the 
risk allele frequency for a certain SNP with its odds ratio. This value was then compared 
to clinical data (death rate for each population) for the certain disease that was observed 
and graphed. 
For each of the steps, tests for statistical bias were conducted. These tests 


















Source vs Other Population 
The results of comparing the RAFs for each of the five main populations are 
shown on Table 1. For the purpose of this report, the data in which Europe was the source 
population will be focused on (however, all five populations were looked at in terms of 
seeing if there were any trends). The data suggests that when looking at GWASs that 
have a European source population, African risk allele frequencies for common diseases 
are higher than European risk allele frequencies. The counts are listed below, and a 
scatter plot (Figure 2) is shown as a visual representation. The shaded regions indicate the 
frequencies in which there is the most power (these are the frequencies that genotyping 
chip arrays (Affymetrix and Illuminia) have the power to detect).  
 
 
Figure 2: EUR vs AFR RAFs (European source population). Risk allele frequencies for independent SNPs are compared for 










EUR-AFR 1658 1777 1 0.042329352 
EUR-EAS 1789 1643 4 0.011014322 
EUR-SAS 1745 1684 7 0.253032888 
EUR-MIX 1665 1771 0 0.073233482 
AFR-EUR 67 47 2 0.050729557 
AFR-EAS 60 55 1 0.642667425 
AFR-SAS 56 58 2 1 
AFR-MIX 64 52 0 0.307089664 
EAS-EUR 366 403 0 0.194187885 
EAS-SAS 358 411 0 0.060699254 
EAS-AFR 352 417 0 0.020944497 
EAS-MIX 345 424 0 0.004879754 
SAS-EUR 19 26 0 0.371298034 
SAS-AFR 24 21 0 0.765991824 
SAS-EAS 27 18 0 0.232693192 
SAS-MIX 26 19 0 0.371298034 
MIX-EUR 257 215 0 0.059021517 
MIX-AFR 230 242 0 0.612681659 
MIX_EAS 248 224 0 0.289744222 
MIX-SAS 242 230 0 0.612681659 
 
Illumina and Affymetrix 
The results at looking at the Illumina and Affymetrix chips are shown in Table 2. 
On both chips, there seems to be an bias towards the African population when compared 
to the European population. Figure 3 shows the mean allele frequency for derived risk 
alleles in source populations compared to each other. The asterisk represents a 
significantly lower value for the mean allele frequency (MAF). Note that the same graph 
was made, except with reference to ancestral alleles. However, it is not shown in this this 
Table 1: Counts of SNPs on which population they were higher for. The first population listed in the 
“Population comparison column is the source population.  Highlighted p-values indicate significant value in terms 
of bias. 
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report. That figure would essentially show that the ancestral mean allele frequency for 
African populations would be significantly higher than the other populations listed. 
 




















EASvsAMR 432962 520190 11036  EASvsAMR 382840 474362 3280 
EASvsAFR 443947 513987 6254  EASvsAFR 397327 461653 1502 
EASvsEUR 439475 472893 51820  EASvsEUR 395889 411053 53540 
EASvsSAS 424361 464689 75138  EASvsSAS 380017 404241 76224 
AMRvsAFR 465186 492402 6600  AMRvsAFR 410149 448390 1943 
AMRvsEUR 497169 453784 13235  AMRvsEUR 469162 386859 4461 
AMRvsSAS 507797 443068 13323  AMRvsSAS 468685 387990 3807 
AFRvsEUR 496927 461199 6062  AFRvsEUR 457709 396641 6132 
AFRvsSAS 490586 467266 6336  AFRvsSAS 450368 404823 5291 
EURvsSAS 457273 452956 53959  EURvsSAS 398900 405421 56161 




Figure 3: Mean allele frequency of derived alleles for each population. The derived allele frequency (DAF) is shown for each 
population as gathered from each genotyping chip technology. The AFR DAF is significantly lower than the other populations.  
 
Ancestral vs Derived 
In addition to trends observed from chip technology, trends in whether or not 
SNPs were ancestral or derived were also looked into. Figures 4 provides a good synopsis 
of general trends that were found. Each dot on the figures represents a sub-population 
(from the 1000 Genomes Project), that makes up on the five main populations (indicated 
by the key). Figure 3 shows the risk allele frequencies for derived alleles versus ancestral 
alleles for cancer alleles for each of the five main populations. The risk allele frequency 
for ancestral alleles in African populations is clearly higher than the risk allele 
frequencies of derived alleles. The opposite can be said for European populations. In East 
Asian populations, there are moderately higher derived allele frequencies than ancestral 
allele frequencies. Both American and South Asian populations tend to be similar to 
* *
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European population trends in this case. Figure 5 shows which SNPs from the EUR vs 
AFR are ancestral and derived. Red indicates derived SNPs, while blue indicates 
ancestral SNPs.  
  
 
Figure 4: Derived vs Ancestral RAFs for cancer in five populations. 
Note that in the key, “Country” is supposed to be “Population.” 
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Figure 5: Ancestral and Derived SNPs from EUR vs AFR Graph.  The EUR vs AFR graph shown beforehand has been colored to 
show which SNPs are derived, and which SNPs are ancestral. 
 
Genetic Risk Score Assessment 
Another comparison that was explored was how well a calculated genetic risk 
score matched up to clinical death rates. For this portion of the study, cancer (all cancers 
in general) SNPs were looked at in calculating GRS and obtaining death rates. Figure 6 
shows this comparison. While AFR populations have a high GRS for cancers, actual 
clinical death rates vary depending on what specific sub-population is being studied. 
While EAS populations have a low GRS, clinical death rates are on the high end for 
cancers. EUR populations have a moderate GRS, however, clinical death rates are high. 
Figure 7 shows the comparison of GRSs for each population for cancers. In this figure, 
the evolutionary history of alleles is taken into account (the specific evolutionary history 
of the allele is indicated by the x and y axis). Isoclines have been added to the graph to 
indicated comparative risk after all the variables have been taken into account. Figure 8 
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shows a bean plot that compares GRSs for cancers for each of the five main populations 
before and after a corrective measure has been applied to the scores. The equation of the 
corrective measures is as follows: 𝐺𝑅𝑆𝑗 = ∑ 𝛽?̅?,𝑗𝑖 . 
 
 
Figure 6: Clinical death rates of cancer in sub-populations vs genetic risk 
scores. The natural log of both variables was used. 
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Figure 7: Comparative GRS graph by Populations. The graph shows comparative risk in terms of a genetic risk 
scores for all cancers. The diagonal isoclines indicated what the numeric value for the GRS (as determined by the 




Figure 8: Corrected GRS bean plot. This figure shows what the GRS for each population is before and 





 Contrary to what was expected, there was a bias towards the African population in 
terms of risk allele frequencies when compared to European population risk allele 
frequencies. It did not matter whether it was raw data (not filtered for a specific source 
population), or even if the source population was European. Because more than 2/3 
 of all GWASs that were recorded on the NHGRI-EBI GWAS Catalog had European 
source populations, it was expected that there would be a bias that over-represents 
European source populations. The results from this study show otherwise (Table 1, 
Figure 1). Table 1 is self-explanatory. It simply shows the counts of risk allele 
frequencies that lean closer to one of the two populations that are compared. Figure 1, 
which is the visual representation of the first row in Table 1, is a lot less clear. In the 
figure, points above the imaginary y=x line are biased towards the European source 
population, while points below this line are biased towards the African population. At 
first glance, it appears that there are more points above the y=x line (indicating a bias 
towards the European population). This is further bolstered by the appearance of an 
abundance of points above the y=x in the lower left quadrant of the figure. However, this 
is not the reality. There are actually more points below the y=x line, leading towards a 
revelation that there is a bias in the African population (if there was no bias, there would 
be an equal amount of points above and below the y=x line). This contrasts what was 
previously found. Carlson and Virlogeux’s studies suggested that GWASs could be 
replicated across populations, meaning that there was no bias, regardless of the source 
population1,2. However, bias is clearly seen here. The presence of bias more closely 
supports the claims of others, that suggest that bias has to be present for one reason or 
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another3,4: Bias could be present due to the genotyping chip that was used to gather the 
genetic data, or the simple fact that gathering genotypic data from a population that holds 
significantly more of one population than others can lead to skewed results. Furthermore, 
it should be noted that the comparison between EUR and AFR is the only comparison 
that is shown in this report. For the most part, a presence of bias is not actually seen in 
significance in other populations (as seen from Table 1). However, in order to prove bias 
in GWAS results from the two databases mentioned, bias only needs to be shown in one 
populations comparison (which is shown in the EUR vs AFR risk allele frequency 
comparison). Therefore, the report has successfully demonstrated that the current data 
that we have from GWAS databases are indeed biased towards at least one specific 
population: The African population. 
Explaining why the bias occurs 
 Since bias, regardless if it was in the expected direction, was found, the next 
logical step in the study was to figure out why, and how, it arose. As mentioned earlier, a 
prime suspect, and where the search began, was with the genotyping chip technology3. 
There are two main chips that are used for the data that was gathered: Illumina 
OmniMetrix and Affymetrix 6.0. Sub-datasets were acquired from the original GWAS 
database and analyzed much the same way as previously mentioned. Each population’s 
frequencies were compared to each other for known disease-related SNPs. Table 2 shows 
the results of this comparison. It appears as if there is no significant difference in bias 
between the two chips when source population was not taken into account. It is important 
to note that the table above does not show comparisons from GWASs of a certain source 
population. While this was actually done, it was later noticed that there was an error in 
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the code, and trends that were seen in that table (not shown) may have been misleading. 
Thus, currently, a new table is being created (but time does not permit it to be shown in 
this report). To further explore the differences in genotyping chip array results, we look at 
what type of alleles are actually being seen by the chips. It is known that both the 
Illumina and Affymetrix chips are enriched for intermediate frequencies: there is a lack 
of statistical power with these chips to record allele frequencies for SNPs that are below 
0.05 and above 0.95. This is represented on Figure 2 (the shaded blue region represents 
the frequencies is SNPs that have a higher chance of actually being seen by current 
technology).  
 Another variable that was looked at was whether or not SNPs being ancestral or 
derived affected overall biased trends. Similar to how the original GWAS dataset was 
split, the dataset that was used for this part of the study split the original GWAS dataset 
by whether or not the SNP was ancestral or derived (as determined by what was labeled 
in the NHGRI-EBI GWAS Catalog). The visual representation of what SNPs were 
ancestral or derived in that EUR vs AFR graph is shown on Figure 5. One can see that 
derived alleles are located in the lower left quadrant, while ancestral alleles are located in 
the upper right quadrant. The spatial location of these evolutionar ily labelled alleles on 
this graph, which represent frequency range location statistically, coupled with the 
understanding that genotyping chip array technology only has statistical power in 
intermediate ranges of frequency, explain why we see the trends that we do on Figure 3. 
Because a majority of GWASs are done in one population, there is a possibility that we 
do not have a good representation of SNP data that is out there. Therefore, the biased 
trends that we see in African populations when compared to European populations can be 
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explained by three things: source population bias, chip array bias, and evolutionary 
history of alleles. The chip array technology used to gather risk allele frequency data for 
disease related SNPs is inherently biased to intermediate frequencies in that of the source 
population. In addition, this is compounded by a lack of incorporation or adherence to the 
evolutionary history of alleles. 
Current effect of this bias 
  From this realization, similar tests were done as previously mentioned to see the 
effect of this bias. Understanding the current trends due to bias is important in figuring 
out how to fix it. However, as opposed to what was done earlier, the RAF for 26 different 
sub-populations were also found for each SNP, as determined by a separate file also 
provided from the 1000 Genomes Project. All the SNPs in figures that are related to 
current trends and genetic risk scores are related to cancer (non-specific), only because 
more data is available in terms of ‘general cancer’ than ‘all common diseases.’ The RAFs 
for derived vs. ancestral cancer SNPs are shown on Figure 4. It appears that the ratio of 
ancestral vs. derived alleles is higher towards the ancestral risk allele frequencies for 
African sub-population SNPs (this further enforces the trend we see with evolutionary 
history of alleles for African risk alleles for all common diseases). The ratio favors 
derived RAFs for East Asian population and European alleles (more noticeable for 
European alleles). Figure 6 shows clinical death rates of cancer for each sub-population 
compared to the calculated genetic risk score (GRS) for cancer for each sub-population. 
The calculation of the GRS is shown in the Results. A GRS is important in this study 
because it is an arbitrary representation of the risk a population has for attaining diseases 
in general (which measures overall healthiness of a population), or specific diseases 
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(which measures the likelihood of an individual in a population getting a diseases). An 
important thing to note is that the GRS for all population for all common diseases or all 
cancers is expected to be similar to each other. At the end of the day, every population is 
still human: no one group of people is inherently unhealthier than other populations. It is 
dangerous to assume so. If one population was unhealthier than the other, we could 
possibly see evidence of this through measured instances of natural selection working 
against that population’s risk for obtaining diseases (such as bolstered innate 
immunity)—but we do not see that.  
 Figure 6 represents the trends that we currently see for cancer related SNPs 
compared to calculated GRS for each population. The figure shows that the death rate for 
African populations, compared to other populations, varies greatly—what is evident is 
that the clinical death rate from cancer for African populations is NOT significantly 
higher than any other population. However, the calculated GRS (as gathered from the 
now-known-to-be biased GWAS data) indicate that African populations have the highest 
risk of getting cancer. The clinical data does not support the GRS data. The divide in 
GRS is more clearly seen in Figure 7. All populations, EXCEPT the African populations, 
are shown to have the same range in GRS (they are located in the same isocline). African 
populations are shown to be a whole isocline (which is a measure of statistical 
significance) higher than the rest. Unfortunately, we know that this measure is not true: 
the reason we see that African populations have a higher risk of getting cancer and ‘all 
common diseases’ is because the GWAS data that we have is biased (for the reasons 
described already). There is an illusion of health disparities right now in the field. This 
illusion can be dangerous: extra resources and suggested screening can be demanded for 
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and by those of African descent, even though they are no more needing of such 
processes. Again, this almost reaches a eugenics level in which we view one population 
as worse off than others—which is not true. In terms of specific diseases, we fully expect 
to see population level differences: however, we cannot trust those results as of right now 
if it is so clearly evident that biased GWASs themselves create this illusion of disparity 
on a more general basis.  
Correcting the bias 
 Now that it is determined that GWASs cannot indeed be generalized across 
population, why they cannot be generalized, and what the effect of this is, the next logical 
step is to try and fix the problem Currently, it is not feasible to demand that all GWASs 
must be redone in different source populations. We must wait for updated genotyping 
chip technology, and demand that GWASs done from now on better depict world 
populations. We can also attempt to correct the data that we have right now. Using a 
corrective factor from the equation presented in the Results, we can attempt to fix the 
problem, Figure 8 shows the application of such a corrective factor applied to GRS. As 
one can see, the corrective factor eliminated bias by applying measures that account for 
evolutionary history of alleles, lack of power in technology, and source population bias. 




 Preventative and predictive healthcare is a growing field of medicine today. 
Ideally, whole genome sequencing for every individual can help prevent and predict 
disease. However, we do not live an ideal world: the cost and effort it takes for whole 
genome sequencing thrusts upon us the realization that alternative methods must be used 
this type of healthcare. A growing trend involves analyzing genome wide association 
studies (GWAS) on a population based level. Risks for certain, specific diseases can be 
measured for each major population by comparing risk allele frequencies of disease-
related single nucleotide polymorphism (SNPs) to each population. Because every 
individual genetically belongs to at least one populations, we can apply these findings on 
an individual level as well. 
 However, if society is to use GWAS data, it must ensure that the dataset is 
unbiased and accurate. This study sought determine is bias exists within the GWAS 
database that skews risk allele frequency for at least one populations. The results of this 
study indicate that bias does indeed exist, especially evident when one compares 
European RAFs to African RAFs. There seems to be a bias towards the African 
populations, creating a representation of elevated risk for all common disease, and all 
cancers in general compared to other populations. 
 This bias can be explained by three connected notions: 1) source population bias, 
2) genotyping chip array bias, and 3) evolutionary history of alleles bias. The lack of 
technology to incorporate the evolutionary history of alleles and its lack of accurately 
reporting allele frequencies outside an intermediate range compounds the negative 
implications of having a majority of GWASs done in one source population (European).   
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 The effect of such a bias creates an illusion of health disparities that show the 
African populations more at risk for all common diseases and all cancers than the other 
populations. This disparity realistically cannot exist due to the fact that there is no 
evidence or expectation that one population is generally worse off in terms of general 
health than the others. If this disparity continues to exist, the potential for misuse of 
allocating resources and the potential for eugenics reaches an uncomfortable level.  
 Preliminary corrective factors have been applied to current genetic risk scores to 
try and mitigate these biases. The resulting genetic risk scores succeed in this regards. 
However, more work must be done to ensure that the corrective measures are appropriate, 
and all biases are accounted for.  
 This study is important in that ensures an important database that is used in a 
growing field of healthcare is unbiased and accurate. The possible risk from using such a 
biased dataset are great. Thankfully, the bias has been early, along with its causes. The 
scientific world can now focus on correcting the lack of generalization from GWASs, and 






 Future work in this study primarily involves ensuring that the corrective factor 
can be applied to all GRSs. In addition, we must ensure that the corrective factor can 
remain prominent when more SNP data is added to the GWAS databases. This may entail 
reworking the equation that has been made already. On a less optimistic note, this may 
mean that a corrective factor can never really be used (if a new corrective factor is needed 
every time a sizeable amount of new SNP data is added to the databases, the overall 
purpose of a definitive corrective factor is lost). At this point, redoing previous GWASs 
in all populations as opposed to just one population may be the only result. To determine 
if this is the case, simulations using the University of Michigan’s GAS-Powered 
Simulator will be run to determine the efficacy of such corrective factor(s).  
 Lastly, the same overall process as described in this study can be done to other 
population comparisons—as a result, different biases towards other populations may still 
exist. Future work includes exploring the other populations comparisons in as much 
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